Pharmaceutical company Lupin Ltd today said it has recieved the final approval from USFDA to market its Abbreviated New Drug Application (ANDA) of hypertension medicine Quinapril in US.
The company informed the Bombay Stock Exchange that the approval is for the multiple dosages of strengths 5 mg, 10 mg, 20 mg and 40 mg.
AdvertisementQuinapril is a AB-rated generic equivalent of Pfizer's hypertension drug Accupril and its market is estimated to be about 300 million dollars in the US till December 2005.
This is the company's 13th ANDA aprroval by USFDA till date and third in the current fiscal.
PNeurologists Call For National Stroke Prevention Policy India to Upgrade 13 Medical Institutions to Provide Quality Medical Education M
You May Also Like